AlphAIalphai — Financial news for AI agents
gurufocus.comAUG 262 min read$ZYME

ZYME Looks 47.1% Overvalued on GF Value™

Zymeworks Inc (ZYME) shares rose 8% after FDA approval of Jazz Pharmaceuticals' Ziihera, triggering a $250M payment. ZYME's P/S ratio is 59.82x, higher than its historical median. Analysts set price targets at $55 and $40. The company's GF Score is 60, indicating moderate fundamental quality. Insiders sold $4.7M in shares over the past year.

Original reporting
gurufocus.com
Published Aug 26, 2026, 4:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 5:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefRegulation
Primary signal
$ZYME
Bullish
high confidence
Mentioned
$ZYME
Relevance
9/10
alphai data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ZYMEBullishHigh
01

Why it matters

The $250 M milestone provides near‑term liquidity and validates the commercial potential of Ziihera, likely supporting the stock’s momentum.

02

Market read

Regulatory approval creates a clear catalyst for ZYME and may influence peer biotech valuations.

03

What to watch

Insider selling and guru trimming suggest caution; future milestone payments depend on commercial success of Ziihera.

Relevance 9/10Novelty 9/10Timing: same‑day release on August 26 2026

Background

Zymeworks is a clinical‑stage biotech that licenses its assets; the FDA approval validates its partnership strategy.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

FDA approval of two Ziihera regimens triggered a $250 million milestone payment and an 8% share surge.

Expected impact

short‑term bullish pressure; potential continuation if commercialization proceeds.

Evidence & confidence

The approval is a primary, material event with a sizable cash infusion and immediate price reaction.

Market effects

Sector

Biotech sector may see heightened interest in licensing deals and FDA‑driven catalysts.

Regional

North American biotech indices could receive a modest lift.

Global

Limited to companies with similar partnership models; no broad macro effect.

Counterpoint

What could challenge this read

High valuation multiples (P/S ≈ 60x) and ongoing cash‑flow negativity could limit upside despite the payment.

Key entities

  • company
    Zymeworks Inc

    Clinical‑stage biotech receiving FDA approval for partnered regimens.

  • company
    Jazz Pharmaceuticals

    Licensee of Ziihera; responsible for the $250 M milestone payment.

Read at source← All news

Related articles

AUG 26
$ZYMEHighAI 9/10

FDA approves new indications for Ziihera

Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals (JAZZ), received FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma. This is the second FDA approval for zanidatamab in under two years, validating Zymeworks' Azymetric platform.

thepharmaletter.com2 min
AUG 26
$ZYMEHighAI 9/10

H.C. Wainwright raises Zymeworks stock price target to $55 on FDA approval

H.C. Wainwright raised its price target on Zymeworks (ZYME) to $55 from $51, maintaining a Buy rating after FDA approval of Ziihera for HER2-positive gastroesophageal adenocarcinoma. The stock is up 85% over the past year. The approval triggers a $250 million payment from Jazz Pharmaceuticals (JAZZ). Analysts predict 188% revenue growth for FY2026. Zymeworks also announced an acquisition of Theravance Biopharma for $929 million.

investing.com2 min
AUG 25
$ZYMEHighAI 8/10

Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab

Zymeworks (ZYME) shares rose 4% in pre-market trading ahead of an FDA decision on zanidatamab, a HER2-targeting antibody, with a PDUFA target date of August 25, 2026. Approval could trigger a $250 million milestone payment and up to $190 million more in other markets. Analysts have increased price targets ahead of the decision. The company is also pursuing a $929 million acquisition of Theravance Biopharma, expected to close in late 2026.

yahoo.com2 min
AUG 25
$ZYMEHighAI 9/10

Zymeworks Inc.: U.S. FDA Approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Zymeworks Inc. (ZYME) announced FDA approval for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line HER2+ GEA treatment. This marks the second FDA approval for zanidatamab in under two years, triggering a $250 million milestone payment from Jazz Pharmaceuticals. Zymeworks could receive up to $1.3 billion in additional milestones and royalties from Jazz, and up to $144 million from BeOne Medicines. The approval is based on Phase 3 trial resul

finanznachrichten.de2 min
AUG 24
$ZYMEMed

Why is Zymeworks stock surging today?

Zymeworks (ZYME) stock rose 4% in pre-market trading ahead of an FDA decision on its HER2-targeting antibody, zanidatamab, which could trigger a $250M milestone payment. Analysts raised price targets, and the company's acquisition of Theravance Biopharma for $929M adds to investor optimism, despite a weak broader market.

investing.com2 min